Peptic ulcer is caused by an imbalance between aggressive and protective factors in the stomach and duodenum. Key contributing factors include H. pylori infection, NSAID use, smoking, stress, and alcohol consumption. Treatment involves acid-suppressing drugs like antacids, H2 receptor antagonists, proton pump inhibitors, and prostaglandin analogues. Antacids provide fast relief but have short duration, while proton pump inhibitors more effectively reduce acid production for longer periods.
This document discusses pharmacotherapy for peptic ulcer disease. It outlines the physiology of gastric acid secretion stimulated by various phases. Peptic ulcer disease is defined as an erosion of the gastrointestinal tract exposed to acid and pepsin. Causes include Helicobacter pylori, NSAIDs, alcohol, stress, and steroids. Therapies aim to enhance defenses or eliminate aggressive factors like H. pylori. Drug classes discussed are antacids, H2 receptor antagonists, prostaglandin analogues, and antibiotics for H. pylori.
This document discusses drugs used to treat peptic ulcers and gastroesophageal reflux disease (GERD). It begins by defining peptic ulcers and their causes, including an imbalance between aggressive and defensive factors in the gastrointestinal tract. It then covers the different types of ulcers and regulators of gastric acid secretion. The document categorizes and describes the mechanisms and uses of several classes of drugs: H2 antagonists like cimetidine and ranitidine; proton pump inhibitors like omeprazole; prostaglandin analogues like misoprostol; antacids; and anti-H. pylori drugs. It discusses the interactions, adverse effects, and treatment of peptic ulcers, G
This document discusses the pathophysiology and treatment of peptic ulcers. It begins by describing the physiology of gastric acid secretion and the roles of histamine, gastrin, and acetylcholine. It then covers various drug classes that reduce acid secretion, including H2 blockers like cimetidine and ranitidine, and proton pump inhibitors like omeprazole. It also discusses antacids, mucosal protectives, and anti-H. pylori regimens. Key treatment strategies include reducing acid with proton pump inhibitors, neutralizing acid with antacids, protecting the mucosa with drugs like sucralfate, and eradicating H. pylori with triple therapy combinations
Drugs used in treatment Peptic ulcer treatment MBBS pptxjagadeesh41693
This document discusses the pathophysiology and treatment of peptic ulcers. It begins by outlining the causes of peptic ulcers including genetic and environmental factors. It then describes the physiology of gastric acid secretion and its regulation. Several classes of drugs are discussed that inhibit acid secretion including H2 receptor blockers, proton pump inhibitors, and prostaglandin analogues. Antacids and other agents that coat the stomach lining are also summarized. Specific drugs are highlighted within each class. The roles of Helicobacter pylori infection and various antibiotic regimens for its treatment are briefly covered.
Peptic Ulcer Disease Affects All Age Groups. Can occur in children, although rare. Duodenal ulcers tends to occur first at around the age 25 and continue until the age of 75. Gastric ulcers peak in people between the ages of 55 and 65. Men Have Twice The Risk as Women Do
Anti Ulcer drugs pharmacology and classificationImtiyaz60
This document summarizes drugs used to treat peptic ulcers. It discusses the anatomy and physiology of gastric acid secretion regulated by histamine, acetylcholine, and gastrin. It describes prostaglandins' protective role in the stomach and how H2 receptor blockers and proton pump inhibitors work to suppress acid secretion. H2 blockers competitively inhibit histamine receptors, while PPIs irreversibly inactivate the proton pump. Common medications discussed include cimetidine, ranitidine, famotidine, omeprazole, and lansoprazole. The goals of anti-ulcer therapy are relieving pain, promoting healing, and preventing complications and relapse.
This document discusses pharmacotherapy for peptic ulcer disease. It outlines the physiology of gastric acid secretion stimulated by various phases. Peptic ulcer disease is defined as an erosion of the gastrointestinal tract exposed to acid and pepsin. Causes include Helicobacter pylori, NSAIDs, alcohol, stress, and steroids. Therapies aim to enhance defenses or eliminate aggressive factors like H. pylori. Drug classes discussed are antacids, H2 receptor antagonists, prostaglandin analogues, and antibiotics for H. pylori.
This document discusses drugs used to treat peptic ulcers and gastroesophageal reflux disease (GERD). It begins by defining peptic ulcers and their causes, including an imbalance between aggressive and defensive factors in the gastrointestinal tract. It then covers the different types of ulcers and regulators of gastric acid secretion. The document categorizes and describes the mechanisms and uses of several classes of drugs: H2 antagonists like cimetidine and ranitidine; proton pump inhibitors like omeprazole; prostaglandin analogues like misoprostol; antacids; and anti-H. pylori drugs. It discusses the interactions, adverse effects, and treatment of peptic ulcers, G
This document discusses the pathophysiology and treatment of peptic ulcers. It begins by describing the physiology of gastric acid secretion and the roles of histamine, gastrin, and acetylcholine. It then covers various drug classes that reduce acid secretion, including H2 blockers like cimetidine and ranitidine, and proton pump inhibitors like omeprazole. It also discusses antacids, mucosal protectives, and anti-H. pylori regimens. Key treatment strategies include reducing acid with proton pump inhibitors, neutralizing acid with antacids, protecting the mucosa with drugs like sucralfate, and eradicating H. pylori with triple therapy combinations
Drugs used in treatment Peptic ulcer treatment MBBS pptxjagadeesh41693
This document discusses the pathophysiology and treatment of peptic ulcers. It begins by outlining the causes of peptic ulcers including genetic and environmental factors. It then describes the physiology of gastric acid secretion and its regulation. Several classes of drugs are discussed that inhibit acid secretion including H2 receptor blockers, proton pump inhibitors, and prostaglandin analogues. Antacids and other agents that coat the stomach lining are also summarized. Specific drugs are highlighted within each class. The roles of Helicobacter pylori infection and various antibiotic regimens for its treatment are briefly covered.
Peptic Ulcer Disease Affects All Age Groups. Can occur in children, although rare. Duodenal ulcers tends to occur first at around the age 25 and continue until the age of 75. Gastric ulcers peak in people between the ages of 55 and 65. Men Have Twice The Risk as Women Do
Anti Ulcer drugs pharmacology and classificationImtiyaz60
This document summarizes drugs used to treat peptic ulcers. It discusses the anatomy and physiology of gastric acid secretion regulated by histamine, acetylcholine, and gastrin. It describes prostaglandins' protective role in the stomach and how H2 receptor blockers and proton pump inhibitors work to suppress acid secretion. H2 blockers competitively inhibit histamine receptors, while PPIs irreversibly inactivate the proton pump. Common medications discussed include cimetidine, ranitidine, famotidine, omeprazole, and lansoprazole. The goals of anti-ulcer therapy are relieving pain, promoting healing, and preventing complications and relapse.
This document discusses various drugs used to treat gastrointestinal conditions. It covers drugs that act on the gastrointestinal tract like antacids, H2 receptor blockers, proton pump inhibitors, cytoprotectants, antidiarrheals, and antibiotics for H. pylori eradication. It discusses their mechanisms of action, uses, and side effects. Laxatives are also covered, with classifications and mechanisms of different types.
Gastrointestinal drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility, water flow, and improve digestion.
This document discusses the pharmacotherapy of peptic ulcers. It begins by classifying the main drugs used: 1) those that inhibit gastric acid secretion like H2 blockers and proton pump inhibitors, 2) antacids that neutralize acid, 3) ulcer protectives like sucralfate, and 4) anti-H. pylori drugs for eradication. It then goes into detail about the mechanisms, uses, and side effects of the major drug classes. H2 blockers competitively block H2 receptors to suppress acid secretion. Proton pump inhibitors irreversibly inactivate the H+/K+ ATPase pump for prolonged acid inhibition. Antacids chemically neutralize acid. Sucralfate
This document discusses the pharmacotherapy of peptic ulcer disease. It begins by describing the physiology of gastric acid secretion and the factors that regulate it. It then discusses peptic ulcer disease itself, including its epidemiology, symptoms, and pathophysiology. The main part of the document covers the various drugs used to treat peptic ulcers, including proton pump inhibitors, H2 receptor antagonists, prostaglandin analogues, anticholinergics, antacids, and ulcer protectives. It also discusses antimicrobial drugs for H. pylori eradication, commonly used combination therapies, and treatments for resistant H. pylori infections.
This document summarizes drugs used to treat gastrointestinal disorders. It discusses drugs for peptic ulcers and GERD, including H2 blockers like ranitidine, proton pump inhibitors like omeprazole, and anti-H. pylori regimens. It also covers antacids, antiemetics, prokinetic drugs, and 5-HT3 antagonists used to treat nausea and vomiting. The mechanisms of action, uses, and side effects of these various drug classes are presented.
This presentation discusses the causes, symptoms, classification and treatment of peptic ulcers. It begins with an introduction defining ulcers and their locations in the stomach and duodenum. The main causes of ulcers are identified as alcohol, NSAIDs, smoking, stress and Zollinger-Ellison syndrome. Common symptoms include epigastric pain relieved by food or antacids. The presentation then classifies treatments for ulcers including anti-secretory agents like H2 receptor antagonists and proton pump inhibitors, anticholinergic drugs, prostaglandin analogues, antacids, and anti-H. pylori treatments. Sucralfate is also discussed as an ulcer protective agent.
This document discusses the pharmacotherapy of peptic ulcers. It begins by outlining the objectives of regulating gastric acid secretion, classifying drugs used to treat ulcers, and their mechanisms of action. It then provides details on the anatomy and physiology of gastric acid secretion and the factors that can disrupt the gastric mucosal barrier and lead to ulcer formation. The document classifies and describes the mechanisms, uses, and side effects of H2 blockers, proton pump inhibitors, antacids, and other drugs used to treat Helicobacter pylori infections and protect the stomach lining.
This document discusses pharmacotherapy for peptic ulcer disease. It begins by defining peptic ulcers and their causes, which include excess acid production, Helicobacter pylori infection, NSAID use, and stress. It then describes various drug classes used to treat peptic ulcers, including H2 antagonists like cimetidine and ranitidine, proton pump inhibitors like omeprazole, prostaglandin analogues like misoprostol, and ulcer protectives like sucralfate. It provides details on the mechanisms and uses of these drug classes and compares their effectiveness, safety profiles, and drug interactions. Antacids are also briefly discussed.
Peptic ulcer disease is caused by a disturbance in the mucosal barrier that protects the stomach and duodenum from acid and pepsin. This allows acid and pepsin to damage the lining and cause ulcers. Treatment involves reducing acid production through proton pump inhibitors or H2 blockers. Additional treatments include antacids to neutralize acid, ulcer protectives like sucralfate to form a protective barrier, and multi-drug regimens to eliminate the bacteria H. pylori when present. Lifestyle changes and avoidance of NSAIDs and smoking are also important parts of treatment and management.
This document discusses anti-ulcer agents. It defines peptic ulcers as erosions in the stomach or duodenum lining caused by an imbalance between aggressive factors like acid and protective factors. Common causes of ulcers include H. pylori, NSAIDs, and stress. Treatment approaches aim to reduce acid secretion using H2 blockers, proton pump inhibitors, anticholinergics, and prostaglandins. Other approaches neutralize acid with antacids, protect the ulcer with sucralfate or bismuth, and eradicate H. pylori with antibiotic combinations.
Peptic ulcers are open sores that develop on the inside lining of esophagus, stomach and/or the upper portion of small intestine. Peptic ulcer occur mainly due to imbalance between aggressive and defensive factors in the stomach.
This document summarizes drugs that affect the gastrointestinal tract. It discusses diseases of the GI tract and how drugs are organized based on the part of the tract they target. Key drug classes covered include H2 blockers, proton pump inhibitors, antacids, antiemetics, antibiotics, and more. The mechanisms and uses of these various drug classes are outlined in detail.
Treatment of acid peptic disease involves drugs that inhibit or neutralize gastric acid secretion. This includes antacids, proton pump inhibitors, H2 blockers, and mucosal protective agents. Antacids are weak bases that neutralize acid. PPIs and H2 blockers suppress acid secretion through inhibition of the proton pump and H2 receptors, respectively. Mucosal protective agents like sucralfate and bismuth compounds coat ulcers to protect from acid and pepsin damage. Eradication of Helicobacter pylori, which causes ulcers and increases cancer risk, requires combination antibiotic and acid suppression therapy.
The document discusses various topics related to anti-ulcer drugs:
1) It describes the mechanisms of common anti-ulcer drug classes including H2 receptor antagonists, proton pump inhibitors, prostaglandin analogues, and anti-H. pylori drugs.
2) It summarizes the structures, mechanisms of action, and uses of representative drugs from these classes like ranitidine, omeprazole, and misoprostol.
3) It explains the roles of gastric acid secretion, H. pylori infection, and mucosal defense in ulcer formation and how different drug classes address these factors.
This document discusses approaches for treating peptic ulcers. It outlines the pathogenesis of peptic ulcers as being caused by an imbalance between aggressive factors like acid and pepsin and defensive factors. The goals of anti-ulcer therapy are relief of pain, ulcer healing, prevention of complications, and prevention of relapse. Major approaches include reducing gastric acid secretion using H2 blockers like cimetidine and ranitidine or proton pump inhibitors like omeprazole. Other approaches are neutralizing gastric acid with antacids, using ulcer protectives like sucralfate, treating H. pylori infections, and reducing acid secretion with anticholinergics like pirenzepine. Specific drugs are discussed
The document discusses various drugs that affect the gastrointestinal system. It reviews drugs that affect GI secretions like histamine H2 receptor blockers, antacids, proton pump inhibitors, mucosal protectants, and prostaglandin analogs. It then focuses on H2 blockers, antacids, proton pump inhibitors, the mucosal protectant sucralfate, and the prostaglandin analog misoprostol, describing their mechanisms of action, clinical uses, precautions, side effects, and drug interactions. The document also briefly mentions the therapeutic indications of laxatives.
This document summarizes peptic ulcer disease. It begins by defining peptic ulcers as lesions in the stomach or duodenum caused by gastric acid and pepsin. Risk factors for peptic ulcers include an imbalance between aggressive factors like acid and protective mucosal defenses. Common symptoms are epigastric pain and weight loss. Treatment approaches aim to reduce acid secretion through H2 blockers, proton pump inhibitors, anticholinergics, and prostaglandin analogues. Other treatments include antacids to neutralize acid, ulcer protectives like sucralfate, and anti-H. pylori drugs to eradicate H. pylori infections which are a major cause of peptic ul
Presentation on Antacids and antiulcer drugs. Introduction to ulcers, classification of antiulcer drugs, their pharmacological actions, uses and adverse effects.
This document provides an overview of peptic ulcer disease. It defines peptic ulcers and discusses their main causes including Helicobacter pylori infection, NSAID use, and Zollinger-Ellison syndrome. It then describes the mechanisms of gastric acid secretion and the goals of antiulcer treatment. Several classes of drugs are covered including those that reduce acid secretion like H2 blockers and proton pump inhibitors, antacids that neutralize acid, and treatments for H. pylori infection. Key learning objectives are outlined for understanding peptic ulcer disease and its pharmacologic management.
Sports medicine aims to prevent and treat injuries in athletes. It also provides guidelines on drugs and doping to protect athletes' health and the integrity of competition. Doping refers to the use of banned substances or methods to enhance performance and gain an unfair advantage. The World Anti-Doping Agency (WADA) was established to harmonize anti-doping policies worldwide and prohibits various substances and methods that pose health risks or violate the spirit of sport, such as anabolic steroids, human growth hormone, blood doping, and gene doping. Athletes undergo in-competition and out-of-competition drug testing to detect the use of prohibited substances and ensure clean competition.
This document discusses various drugs used to treat gastrointestinal conditions. It covers drugs that act on the gastrointestinal tract like antacids, H2 receptor blockers, proton pump inhibitors, cytoprotectants, antidiarrheals, and antibiotics for H. pylori eradication. It discusses their mechanisms of action, uses, and side effects. Laxatives are also covered, with classifications and mechanisms of different types.
Gastrointestinal drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility, water flow, and improve digestion.
This document discusses the pharmacotherapy of peptic ulcers. It begins by classifying the main drugs used: 1) those that inhibit gastric acid secretion like H2 blockers and proton pump inhibitors, 2) antacids that neutralize acid, 3) ulcer protectives like sucralfate, and 4) anti-H. pylori drugs for eradication. It then goes into detail about the mechanisms, uses, and side effects of the major drug classes. H2 blockers competitively block H2 receptors to suppress acid secretion. Proton pump inhibitors irreversibly inactivate the H+/K+ ATPase pump for prolonged acid inhibition. Antacids chemically neutralize acid. Sucralfate
This document discusses the pharmacotherapy of peptic ulcer disease. It begins by describing the physiology of gastric acid secretion and the factors that regulate it. It then discusses peptic ulcer disease itself, including its epidemiology, symptoms, and pathophysiology. The main part of the document covers the various drugs used to treat peptic ulcers, including proton pump inhibitors, H2 receptor antagonists, prostaglandin analogues, anticholinergics, antacids, and ulcer protectives. It also discusses antimicrobial drugs for H. pylori eradication, commonly used combination therapies, and treatments for resistant H. pylori infections.
This document summarizes drugs used to treat gastrointestinal disorders. It discusses drugs for peptic ulcers and GERD, including H2 blockers like ranitidine, proton pump inhibitors like omeprazole, and anti-H. pylori regimens. It also covers antacids, antiemetics, prokinetic drugs, and 5-HT3 antagonists used to treat nausea and vomiting. The mechanisms of action, uses, and side effects of these various drug classes are presented.
This presentation discusses the causes, symptoms, classification and treatment of peptic ulcers. It begins with an introduction defining ulcers and their locations in the stomach and duodenum. The main causes of ulcers are identified as alcohol, NSAIDs, smoking, stress and Zollinger-Ellison syndrome. Common symptoms include epigastric pain relieved by food or antacids. The presentation then classifies treatments for ulcers including anti-secretory agents like H2 receptor antagonists and proton pump inhibitors, anticholinergic drugs, prostaglandin analogues, antacids, and anti-H. pylori treatments. Sucralfate is also discussed as an ulcer protective agent.
This document discusses the pharmacotherapy of peptic ulcers. It begins by outlining the objectives of regulating gastric acid secretion, classifying drugs used to treat ulcers, and their mechanisms of action. It then provides details on the anatomy and physiology of gastric acid secretion and the factors that can disrupt the gastric mucosal barrier and lead to ulcer formation. The document classifies and describes the mechanisms, uses, and side effects of H2 blockers, proton pump inhibitors, antacids, and other drugs used to treat Helicobacter pylori infections and protect the stomach lining.
This document discusses pharmacotherapy for peptic ulcer disease. It begins by defining peptic ulcers and their causes, which include excess acid production, Helicobacter pylori infection, NSAID use, and stress. It then describes various drug classes used to treat peptic ulcers, including H2 antagonists like cimetidine and ranitidine, proton pump inhibitors like omeprazole, prostaglandin analogues like misoprostol, and ulcer protectives like sucralfate. It provides details on the mechanisms and uses of these drug classes and compares their effectiveness, safety profiles, and drug interactions. Antacids are also briefly discussed.
Peptic ulcer disease is caused by a disturbance in the mucosal barrier that protects the stomach and duodenum from acid and pepsin. This allows acid and pepsin to damage the lining and cause ulcers. Treatment involves reducing acid production through proton pump inhibitors or H2 blockers. Additional treatments include antacids to neutralize acid, ulcer protectives like sucralfate to form a protective barrier, and multi-drug regimens to eliminate the bacteria H. pylori when present. Lifestyle changes and avoidance of NSAIDs and smoking are also important parts of treatment and management.
This document discusses anti-ulcer agents. It defines peptic ulcers as erosions in the stomach or duodenum lining caused by an imbalance between aggressive factors like acid and protective factors. Common causes of ulcers include H. pylori, NSAIDs, and stress. Treatment approaches aim to reduce acid secretion using H2 blockers, proton pump inhibitors, anticholinergics, and prostaglandins. Other approaches neutralize acid with antacids, protect the ulcer with sucralfate or bismuth, and eradicate H. pylori with antibiotic combinations.
Peptic ulcers are open sores that develop on the inside lining of esophagus, stomach and/or the upper portion of small intestine. Peptic ulcer occur mainly due to imbalance between aggressive and defensive factors in the stomach.
This document summarizes drugs that affect the gastrointestinal tract. It discusses diseases of the GI tract and how drugs are organized based on the part of the tract they target. Key drug classes covered include H2 blockers, proton pump inhibitors, antacids, antiemetics, antibiotics, and more. The mechanisms and uses of these various drug classes are outlined in detail.
Treatment of acid peptic disease involves drugs that inhibit or neutralize gastric acid secretion. This includes antacids, proton pump inhibitors, H2 blockers, and mucosal protective agents. Antacids are weak bases that neutralize acid. PPIs and H2 blockers suppress acid secretion through inhibition of the proton pump and H2 receptors, respectively. Mucosal protective agents like sucralfate and bismuth compounds coat ulcers to protect from acid and pepsin damage. Eradication of Helicobacter pylori, which causes ulcers and increases cancer risk, requires combination antibiotic and acid suppression therapy.
The document discusses various topics related to anti-ulcer drugs:
1) It describes the mechanisms of common anti-ulcer drug classes including H2 receptor antagonists, proton pump inhibitors, prostaglandin analogues, and anti-H. pylori drugs.
2) It summarizes the structures, mechanisms of action, and uses of representative drugs from these classes like ranitidine, omeprazole, and misoprostol.
3) It explains the roles of gastric acid secretion, H. pylori infection, and mucosal defense in ulcer formation and how different drug classes address these factors.
This document discusses approaches for treating peptic ulcers. It outlines the pathogenesis of peptic ulcers as being caused by an imbalance between aggressive factors like acid and pepsin and defensive factors. The goals of anti-ulcer therapy are relief of pain, ulcer healing, prevention of complications, and prevention of relapse. Major approaches include reducing gastric acid secretion using H2 blockers like cimetidine and ranitidine or proton pump inhibitors like omeprazole. Other approaches are neutralizing gastric acid with antacids, using ulcer protectives like sucralfate, treating H. pylori infections, and reducing acid secretion with anticholinergics like pirenzepine. Specific drugs are discussed
The document discusses various drugs that affect the gastrointestinal system. It reviews drugs that affect GI secretions like histamine H2 receptor blockers, antacids, proton pump inhibitors, mucosal protectants, and prostaglandin analogs. It then focuses on H2 blockers, antacids, proton pump inhibitors, the mucosal protectant sucralfate, and the prostaglandin analog misoprostol, describing their mechanisms of action, clinical uses, precautions, side effects, and drug interactions. The document also briefly mentions the therapeutic indications of laxatives.
This document summarizes peptic ulcer disease. It begins by defining peptic ulcers as lesions in the stomach or duodenum caused by gastric acid and pepsin. Risk factors for peptic ulcers include an imbalance between aggressive factors like acid and protective mucosal defenses. Common symptoms are epigastric pain and weight loss. Treatment approaches aim to reduce acid secretion through H2 blockers, proton pump inhibitors, anticholinergics, and prostaglandin analogues. Other treatments include antacids to neutralize acid, ulcer protectives like sucralfate, and anti-H. pylori drugs to eradicate H. pylori infections which are a major cause of peptic ul
Presentation on Antacids and antiulcer drugs. Introduction to ulcers, classification of antiulcer drugs, their pharmacological actions, uses and adverse effects.
This document provides an overview of peptic ulcer disease. It defines peptic ulcers and discusses their main causes including Helicobacter pylori infection, NSAID use, and Zollinger-Ellison syndrome. It then describes the mechanisms of gastric acid secretion and the goals of antiulcer treatment. Several classes of drugs are covered including those that reduce acid secretion like H2 blockers and proton pump inhibitors, antacids that neutralize acid, and treatments for H. pylori infection. Key learning objectives are outlined for understanding peptic ulcer disease and its pharmacologic management.
Sports medicine aims to prevent and treat injuries in athletes. It also provides guidelines on drugs and doping to protect athletes' health and the integrity of competition. Doping refers to the use of banned substances or methods to enhance performance and gain an unfair advantage. The World Anti-Doping Agency (WADA) was established to harmonize anti-doping policies worldwide and prohibits various substances and methods that pose health risks or violate the spirit of sport, such as anabolic steroids, human growth hormone, blood doping, and gene doping. Athletes undergo in-competition and out-of-competition drug testing to detect the use of prohibited substances and ensure clean competition.
This document discusses antiparasitic agents used to treat various protozoal and helminthic infections. It begins by classifying parasites and listing common protozoal infections and their causative organisms. It then describes various anti-protozoal drugs including their mechanisms of action, pharmacokinetics, therapeutic uses, and adverse effects. Drugs covered include amphotericin B, eflornithine, melarsoprol, nitroimidazoles, miltefosine, nifurtimox/benznidazole, nitazoxanide, paramomycin, pentamidine, sodium stibogluconate, and suramin. The document concludes with a brief section on hel
The document discusses drug dosage forms, which are the various ways that pharmaceutical products are administered to patients. Some key points made:
- Dosage forms provide accurate dosing of drugs and allow for administration through different routes. Common forms include tablets, capsules, injections, etc.
- Formulations specify the name, strength and dosage form of the drug product. Excipients are inactive ingredients that don't affect the drug's therapeutic action.
- The dosage form determines how drug molecules are delivered to sites of action in the body. It must provide protection, accurate dosing, and optimize drug effects.
Bronchial Asthma & COPD Pharmacotherapy
- Bronchial asthma is a chronic inflammatory disease of the airways that affects hundreds of millions worldwide. Common symptoms include wheezing, coughing, shortness of breath, and chest tightness.
- The main drug classes for treatment are bronchodilators, corticosteroids, mast cell stabilizers, anti-leukotrienes, and monoclonal antibodies. Drugs are primarily delivered via inhalation for direct action in the lungs with fewer systemic side effects.
- Short-acting beta-2 agonists are used for acute attacks while long-acting ones provide prolonged bronchodilation. Inhaled corticosteroids are first-
PH 1.3 Drug formulations & drug delivery systems_1.1 - Copy.pptxVikramSharma288
This document discusses drug dosage forms, formulations, and delivery systems. It begins by defining the difference between a dosage form and a formulation. Various common dosage forms are described including tablets, capsules, liquids, and semisolids. Formulations include the specific drug, strength, and dosage form. The document then discusses excipients and how they are included in dosage forms but do not produce therapeutic effects. Various drug delivery systems aim to optimize drug action by ensuring accurate dosing, protecting drugs, and controlling drug release over time. The summary concludes that drug delivery systems aim to deliver pharmaceuticals to the body in a controlled manner to achieve therapeutic effects while reducing unwanted side effects.
This document discusses pharmacokinetics related to drug absorption and distribution. It defines key terms like absorption, bioavailability, bioequivalence, apparent volume of distribution, and plasma protein binding. Several factors that influence drug absorption via different routes of administration are described, including solubility, concentration gradient, vascularity, and drug interactions. Drug distribution is affected by lipid/water solubility, protein binding, tissue affinity, and disease states. The volume of distribution represents the hypothetical volume needed to contain the administered dose at the observed plasma concentration.
This document provides a classification and overview of pathogenic fungi and antifungal drugs. It begins by classifying fungi into yeasts, yeast-like fungi, molds, and dimorphic fungi. It then categorizes fungal infections as superficial, cutaneous, subcutaneous, or systemic/opportunistic. The document further discusses the classification, mechanisms of action, pharmacokinetics, uses, and adverse effects of various antifungal drug classes including polyenes, azoles, allylamines, echinocandins, and others. It provides details on specific drugs like amphotericin B, nystatin, ketoconazole, fluconazole, itraconazole,
Chloramphenicol and tetracyclines are broad-spectrum antibiotics that are bacteriostatic. Their widespread use led to many resistant bacterial strains. Chloramphenicol works by reversibly binding to the 50S ribosomal subunit and inhibiting peptidyl transferase activity. Tetracyclines inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit. Both experience resistance through ribosomal protection, decreased drug permeability/concentration, and enzymatic inactivation. They have many therapeutic uses but also potential adverse effects like bone/tooth discoloration and gastrointestinal issues. Tigecycline is a newer glycylcycline antibiotic with activity against resistant strains.
Dr. Vikram Sharma discusses the history and development of policies and regulations related to orphan drugs and rare diseases. Key events include the establishment of the FDA's Office of Orphan Products Development in 1982 and the passing of the Orphan Drug Act in 1983 in the US. The document outlines incentives provided by various countries and regions to promote research and development of orphan drugs, and challenges that still remain in ensuring access and affordability of treatments for rare diseases.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
2. What is Peptic Ulcer ?
• Peptic ulcer disease (PUD) is characterized by
discontinuation in the inner lining of the
gastrointestinal (GI) tract.
• Gastritis is the precursor to PUD & it is clinically
difficult to differentiate the two.
• Two types -
o Stomach (gastric ulcer)
o Duodenum (duodenal ulcer)
3.
4. Why Ulceration Occurs?
• Destructive mechanisms:
o High [H+] in the gastric lumen
o Require defense mechanisms to protect oesophagus and
stomach
o Oesophagus – LES
• Protective mechanisms:
o Mucus secretion:
o Prostaglandins E2
o Bicabonate ions- Gel like covering
o Mucosal blood flow
7. What may contribute imbalance ?
• Helicobacter pylori
• NSAIDs
• Ethanol
• Tobacco
• Severe physiologic
stress (Burns, CNS trauma,
Surgery, Severe medical illness)
• Steroids
8. H. Pylori
• Gram (‐) rod with flagella
• H pylori is most common cause of
PUD
• Transmission route fecal‐oral
• Secretes urease → convert urea to
ammonia
• Produces alkaline environment
enabling survival in stomach
• Almost all duodenal & 2/3 gastric
ulcer pt’s infected with HP
• Considered class 1 carcinogen →
gastric cancer
• Higher prevalence in Low SES
14. Phases of gastric secretion
Phase Stimuli Pathway
Cephalic (stimulate) Sight, smell, taste or
thought of food
1) Vagus (M3 receptors)
2) Histamine (H2 receptor)
3) Gastrin
Gastric (stimulate) Food in the stomach 1) Stretch: local reflex (M3
receptors)
2) Chemical substances in food
(gastrin)
3) Increase pH: Inhibition of
somatostatin (GHIH) release
Intestinal (inhibit) Chyme in the
duodenum
17. Antacids
• Weak bases that neutralize acid
• Also inhibit formation of pepsin
(pepsinogen converted to pepsin at acidic pH)
• Acid Neutralizing Capacity
o Potency of Antacids
o Expressed in terms of number of mEq of 1N HCl
that are brought down to pH 3.5 in 15 minutes
by unit dose of a preparation (1 gm)
18. Antacids
• Sodium Bicarbonate
o Potent neutralizing capacity & acts instantly
o ANC: 1 gm = 12 mEq
• NOT USED ANYMORE FOR ITS DEMERITS
Systemic alkalosis
Distension, discomfort and belching (CO2)
Rebound acidity
Sodium overload
19. Antacids
• Non-Systemic Antacids :
– Aluminium Hydroxide (ANC 1‐2.5mEq/g)
– Magnesium Hydroxide (ANC 30 mEq) – milk of magnesia
– Magnesium trisilicate (ANC 1mEq/g)
• Duration of action : 30 min when taken in empty stomach & 2
hrs when taken after a meal
• Side effects :
Aluminium: constipation (As they relax gastric smooth muscle
& delay gastric emptying) – also hypophosphatemia &
osteomalcia
Mg2+ – Osmotic diarrhoea
• In renal failure Al3+ antacid – Aluminium toxicity
& Encephalopathy
• Magaldrate – hydrated hydroxy magnesium aluminate)
20. Antacids – contd.
• Simethicone: Decrease surface tension
thereby reduce bubble formation ‐ added to
prevent reflux
• Alginates: Form a layer of foam on top of
gastric contents & reduce reflux
• Oxethazaine: Surface anaesthetic
21. Therapeutic Questions
• Is it rational to combine Aluminium hydroxide
and magnesium hydroxide in antacid
preparations ?
• How to avoid formation of insoluble
complexes of drugs by antacids, that are not
absorbed ?
22. Answers (!)
• Interactions can be avoided by taking antacids
2 hrs before or after ingestion of other drugs
• Combination provides a relatively fast and
sustained neutralizing capacity
– (Magnesium Hydroxide – Rapidly acting
– Aluminium Hydroxide ‐ Slowly acting )
• Combination preserves normal bowel function
– (Aluminium Hydroxide – constipation
– Magnesium hydroxide – diarrhoea )
23. Therapeutic Status
• Over the counter (OTC) drug for symptomatic
relief of dyspepsia
• May only be prescribed for very short term:
o Non‐ulcer dyspepsia & minor episodes of heart
burn
o As adjuvant in GERD; quick relieve
25. Sucralfate
(ulcer protective)
• Salt of sucrose complexed to sulfated aluminium hydroxide (basic
aluminium salt)
• MOA:
– In acidic pH polymerises to viscous gel that adheres to ulcer
crater ‐
more on duodenal ulcer
– Precipitates protein on surface proteins & acts as physical barrier
– Dietary proteins get deposited on this layer forming another coat
– Delays gastric emptying and causes gastric PG synthesis –
protective action
26. Sucralfate
• Concurrent antacids, H2 antagonist avoided (as it
needs acid for activation
• Uses:
o NSAID induced ulcers
o Patients with continued smoking
o ICU
o Topically – burn, bedsore ulcers, excoriated skins
• Dose: 1 gm; 1 hr before meals; empty stomach
• ADRs: Constipation, hypophosphatemia
27. H2 Antagonists
• Cimetidine, Ranitidine, Famotidine, Roxatidine, Nizatidine
and
• MOA:
– Reversible competitive inhibitors of H2 receptor
– Highly selective, no action on H1 or H3 receptors
– All phases of gastric acid secretion
(as it depends
– Very effective in inhibiting nocturnal acid secretion
largely on Histamine )
– Modest impact on meal stimulated acid secretion (as it depends on
gastrin, acetylcholine & histamine)
– Volume of pepsin content and IF are also reduced
– Volume reduced by 60 to 70% ‐ anti ulcerogenic effect
– No effect on motility
28. H2 antagonists
• Kinetics:
– All drugs are absorbed orally adequately
– Bioavailability upto 80 %
– Absorption is not interfered by presence of food
– Can cross placental barrier and reaches milk
– Poor CNS penetration
– 2/3rd of the drugs are excreted unchanged in bile
and urine
• Preparations: tablets, injections
29. H2 antagonists
• ADRs:
• Extremely safe drugs & well tolerated
• Main ADRs are with use of Cimetidine
– Antiandrogenic effects
– Increases prolactin secretion & inhibits degradation of estradiol by
liver → Gynaecomastia, Galactorrhoea. impotence
– Cytochrome P450 inhibition – Caution wih theophylline,
metronidazole, phenytoin, imipramine etc.
• Others:
– Headache, dizziness, bowel upset, dry mouth
– Mental Changes
– Bolus IV → release histamine – bradycardia, arrhythmia, cardiac arrest
(Caution in elderly)
31. H2 antagonists ‐ Uses
• Clinical Uses:
o Duodenal ulcer – 70 to 90%
o Gastric Ulcer – 50 to 75% (NSAID ulcers))
o Stress ulcer and gastritis
o GERD
o Zollinger‐Ellison syndrome
o Prophylaxis of aspiration pneumonia
o Urticaria
• Doses:
300 mg/40 mg/150 mg at bed time of R, F, Rox respectively for
healing
Maintenance: 150/20/150 mg BD of R, F, Rox
33. Proton Pump Inhibitors
• Most effective drugs in antiulcer therapy
• Prodrugs requiring activation in acid environment
• Block enzymes responsible for secreting HCl; binds
irreversibly to H+K+ATPase
• Prototype: Omeprazole (Prilosec)
• Examples:
– Lansoprazole
– Pantoprazole
– Rabeprazole
– Esomeprazole
Omeprazole
34. PPI
• Substituted Benzimidazole derivative
• Prodrug (weak bases) → Diffuses into G. canaliculi → accumulation
pH < 5 (proton catalyzed ) → tetracyclic sulfenamide + sulphenic
Acid →
• Covalent binding with sulfhydryl cysteines of H⁺K⁺
ATPase
• Irreversible inactivation of the pump molecule
(charged forms cannot diffuse back across the canaliculi)
• Acid suppressants regardless of stimulating factors
• Also inhibits gastric mucosal carbonic anhydrase
35. Pharmacokinetics
⋅ I
I
i
Irreversibly inactivate the proton pump molecule but half
life is very short and only 1‐2 Hrs
⋅ Still action persists for 24 Hrs to 48 hrs after a single dose –
irreversible inhibition of PPI → new PP synthesis takes time
(24 to 48 hour suppression of acid secretion
⋅ Plateau state is attained after 4‐5 days of dosing
⋅ Action lasts for 4‐5 days even after stoppage of the drug
36. Question
• Half life of proton pump inhibitors is 1.5 hours
only and these drugs are generally given once
daily. How this can be justified ?
• Answer :
o PPI ‐ Irreversible inhibitors of Proton Pump
(Hit & Run drugs)
37. Pharmacokinetics ‐ PPI
⋅ Given on an empty stomach because food affects absorption
⋅
(
given 30 minutes to 1 hour before food intake) because an acidic
pH in the parietal cell acid canaliculi is required for drug
activation, and food stimulates acid production
⋅ Concomitant use of other antisecretory drugs ‐ H2 receptor
antagonists – reduces action
⋅ Highly protein bound and rapidly Metabolized by the liver by
CYP2C19 and CYP3A4 – dose reduction necessary in severe
hepatic failure
⋅ Excreted in Kidneys minimally (no dose reduction needed in
renal failure & elderly)
38. Adverse Effects
⋅GIT upset in the form of nausea, abdominal pain,
constipation, flatulence, & diarrhea
⋅ Subacute myopathy, arthralgias, headaches, and skin
rashes
⋅Prolonged use:
⋅ Gynaecomastia, erectile dysfunction
⋅ Leucopenia and hepatic dysfunction
⋅ Vitamin B12 deficiency
⋅ Hypergastrinemia which may predispose to rebound
hypersecretion of gastric acid upon discontinuation of
therapy: may promote the growth of gastrointestinal
tumors (carcinoid tumors )
39. PPI – contd.
• Drug Interaction:
– Inhibits metabolism of Warfarin, Diazepam
• Therapeutic uses:
1. Gastroesophageal reflux disease (GERD)
2. Peptic Ulcer ‐ Gastric and duodenal ulcers
3. Bleeding peptic Ulcer
4. Zollinger ellison Syndrome
5. Prevention of recurrence of nonsteroidal antiinflammatory drug
(NSAID) ‐ associated gastric ulcers in patients who continue NSAID
use.
6. Reducing the risk of duodenal ulcer recurrence associated with H.
pylori infections
7. Aspiration Pneumonia
41. Muscarinic Antagonists
o Atropine
– Block the M1 class receptors
– Reduce acid production
– Abolish gastrointestinal spasm
o Pirenzepine & Telenzepine
• Reduce meal stimulated HCl secretion by reversible blockade of
muscarinic (M1) receptors on the cell bodies of the intramural
cholinergic ganglia
(receptors on parietal cells are M3)
• Unpopular as a first choice because of high incidence of
anticholinergic side effects (dry mouth and blurred vision)
42. Prostaglandin analogues
• Inhibit gastric acid secretion
• Exhibit ‘cytoprotective’ activity
• Enhance local production of mucus or bicarbonate
• Promote local cell regeneration
• Help to maintain mucosal blood
43. Prostaglandin analogues ‐
Misoprostol
⚫Actions:
⚫Inhibit histamine‐stimulated gastric acid secretion
⚫Stimulation of mucin and bicarbonate secretion
⚫Increase mucosal blood flow
(Reinforcing of mucous layer buffered by HCO3
secretion from epithelial cells)
⚫Therapeutic uses:
Prevent ion of NSAID‐induced mucosal injury
(rarely used because it needs frequent
administration – 4 times daily)
44. Misoprostol
• Doses: 200 mcg 4 times a day (Misoprost)
• ADRs:
– Diarrhoea and abdominal cramps
– Uterine bleeding
– Abortion
– Exacerbations of inflammatory bowel disease and
should be avoided in patients with this disorder
Contraindications:
1. Inflammatory bowel disease
2. Pregnancy (may cause abortion)
45. Question
A patient comes to your clinic at midnight
complaining of heart burn. You want to
relieve his pain immediately. What drug will
you choose?
46. Answer is
Antacids
• Explanation :
Antacids neutralize the already secreted
acid in the stomach. All other drugs act by
stopping acid secretion and so may not relieve
symptoms atleast for 45 min
47. Eradication of H. Pylori
Omeprazole
Amoxicillin
Clarithromycin
Metronidazole
48. Triple Therapy
The BEST among all the Triple therapy regimen is:
Omeprazole / Lansoprazole
Clarithromycin
Amoxycillin / Metronidazole
- 20 / 30 mg bd
- 500 mg bd
- 1gm / 500 mg bd
Given for 14 days followed by PPI for 4-6 weeks
(
Short regimens for 7-10 days not very effective)
51. Bismuth Subsalicylate
Pharmacological actions:
• Undergoes rapid dissolution in the stomach
into bismuth and salicylates
• Salicylates are absorbed
• Bismuth coats ulcers and erosions protecting
them from acid and pepsin and increases
prostaglandin and bicarbonate production
• Uses:
• Treatment of dyspepsia and acute diarrhoea
52. Question
A pregnant lady (first trimester) comes to you with
peptic ulcer disease. Which drug will you
prescribe for her ?
53. Answer:
Antacids or Sucralfate
Explanation:
H2 antagonists cross placenta & secreted in breast
milk
Safety of proton pump inhibitors not established in
pregnancy.
Misoprostol causes abortion
Editor's Notes
In case of metronidazole resistance replace it with Amoxicillin.